News
- Author:
- Susan London
Publish date: September 27, 2019
The rate of AF was elevated in the first year post diagnosis and after 5 years post diagnosis, with greater elevation for women who received chemot...
News
- Author:
- Susan London
Publish date: September 27, 2019
Male patients had 19% higher 5-year mortality than their female counterparts even after confounders were taken into account.
News
- Author:
- Susan London
Publish date: September 24, 2019
A retrospective cohort study suggests that ASCT, if performed promptly, can be curative in patients who have had an early failure of first-line the...
News
- Author:
- Susan London
Publish date: September 24, 2019
A meta-analysis of 140 trials indicated that combining hormone therapy with targeted therapy led to significantly better efficacy, reducing the ris...
News
- Author:
- Susan London
Publish date: September 20, 2019
Two HIV-positive patients with chemotherapy-refractory, high-grade B-cell lymphoma achieved complete remission with anti-CD19 CAR T-cell therapy, w...
News
- Author:
- Susan London
Publish date: September 19, 2019
This type of imaging altered stage and management in nearly one-fifth of cases.
News
- Author:
- Susan London
Publish date: August 14, 2019
Among postmenopausal patients with node-negative, ER-positive breast cancer, significant benefit of adjuvant tamoxifen over no endocrine therapy wa...
News
- Author:
- Susan London
Publish date: August 13, 2019
Testing commonly revealed actionable aberrations, but only about 1 in 10 usable tests led to a change in patient management, raising questions abou...
News
- Author:
- Susan London
Publish date: August 12, 2019
Adding the antiangiogenic agent to the EGFR tyrosine kinase inhibitor did not significantly prolong PFS and was associated with more grade 3 or wor...
News
- Author:
- Susan London
Publish date: August 5, 2019
The more fat that breast cancer survivors had in the visceral compartment or intramuscular compartment, the higher their CVD risk, regardless of th...
News
- Author:
- Susan London
Publish date: August 5, 2019
With longer follow-up, analyses showed emergence of a significant overall survival benefit of adjuvant chemoradiotherapy over radiotherapy alone, b...
News
- Author:
- Susan London
Publish date: July 29, 2019
Endpoints seen among patients treated with PD-1/PD-L1 inhibitors in real-world settings were consistent within data sets and similar to those obtai...
News
- Author:
- Susan London
Publish date: July 24, 2019
The drug had good antitumor activity in the pretreated trial population, despite high rates of grade 3 or worse treatment-related adverse events an...
News
- Author:
- Susan London
Publish date: July 24, 2019
Durvalumab, with or without tremelimumab, was safe and well tolerated in patients with recurrent or metastatic PDAC, but response rates did not mee...
News
- Author:
- Susan London
Publish date: July 23, 2019
Patients undergoing definitive radiotherapy during a declaration of hurricane disaster had a 21-day longer radiation treatment duration and were 19...
